Related references
Note: Only part of the references are listed.Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
C3inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria
Masatoshi Sakurai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
Antonio M. Risitano et al.
FRONTIERS IN IMMUNOLOGY (2019)
Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US
Jessica J. Jalbert et al.
BLOOD (2019)
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
Austin G. Kulasekararaj et al.
BLOOD (2019)
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Jong Wook Lee et al.
BLOOD (2019)
Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status
Mustafa N. Yenerel et al.
BLOOD CELLS MOLECULES AND DISEASES (2017)
Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
Hirokazu Nakayama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
Jun Ho Jang et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2016)
Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia
W. Barcellini et al.
DISEASE MARKERS (2015)
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
Regis Peffault de Latour et al.
BLOOD (2015)
Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs
Claire F. Snyder et al.
QUALITY OF LIFE RESEARCH (2015)
Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry
Hubert Schrezenmeier et al.
HAEMATOLOGICA (2014)
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
Peter Hillmen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
Amy E. DeZern et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry
Jong Wook Lee et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
James E. Signorovitch et al.
VALUE IN HEALTH (2012)
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Stem cell transplantation for paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
BLOOD (2007)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
A Hill et al.
BLOOD (2005)
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales
D Cella et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2002)
Fatigue in cancer patients compared with fatigue in the general United States population
D Cella et al.
CANCER (2002)
Share Paper
